DNA Collection

Cheek swab performed in physician's office

Turn-around Time

7 to 10 days

Have a question?

References: 1. GlaxoSmithKline. Ziagen medication guide. 1st ed. http://www.fda.gov/downloads/Drugs/DrugSafety/ucm224556.pdf. Published September 2015. Accessed February 19, 2016. 2. U.S. Food and Drug Administration. Abacavir. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020977s030,020978s034lbl.pdf. Published September 2015. Accessed February 19, 2016. 3. World Health Organization. 19th WHO model list of essential medicines. 1st ed. http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf. Published April 2015. Accessed February 19, 2016. 4. Escaut L, Liotier J, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS. 1999;13(11):1419. doi:10.1097/00002030-199907300-00026. 5. Hetherington S, McGuirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23(10):1603-1614. doi:10.1016/s0149-2918(01)80132-6. 6. Easterbrook P, Waters A, Murad S et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med. 2003;4(4):321-324. doi:10.1046/j.1468-1293.2003.00166.x. 7. Martin M, Hoffman J, Freimuth R et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and abacavir dosing: 2014 update. Clin Pharmacol Ther. 2014;95(5):499-500. doi:10.1038/clpt.2014.38. 8. U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 1st ed. https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Updated January 28, 2016. Accessed February 19, 2016. 9. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernández-Viña M. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol. 2001;62(9):1009-1030. doi:10.1016/s0198-8859(01)00298-1. 10. Orkin C, Sadiq S, Rice L, Jackson F. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B * 5701 in HIV-1-infected UK subjects. HIV Med. 2010;11(3):187-192. doi:10.1111/j.1468-1293.2009.00762.x. 11. Jagannathan L, Chaturvedi M, Satish B et al. HLA-B*57:01 and gender influence the occurrence of tuberculosis in HIV infected people of South India. Clin Dev Immunol. 2011;2011:1-8. doi:10.1155/2011/549023. 12. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358(6):568-579. doi:10.1056/nejmoa0706135. 13. Schackman B, Scott C, Walensky R, Losina E, Freedberg K, Sax P. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22(15):2025-2033. doi:10.1097/qad.0b013e3283103ce6. 14. Hughes D, Vilar F, Ward C, Alfirevic A, Park B, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004;14(6):335-342. doi:10.1097/00008571-200406000-00002.15. Günthard H, Aberg J, Eron J et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410. doi:10.1001/jama.2014.8722.